Americans are facing more shortages of the drugs they need for medical care than ever before, a national pharmacy database ...

Lilly recently announced news that could solve a big problem.

However, corresponding drug prices have long been an animating issue in ... To encourage generics to challenge branded drugmakers’ patents — thereby potentially getting their products to market sooner ...

DRUGMAKERS DOMINATE TOP LOBBYING SPENDERS — The pharmaceutical industry bolstered its lobbying spending in the first three months of 2024 compared with the same period in 2023, according to newly ...

Myrbetriq – sold as Betanis and Betmiga in some markets – is an extended-release selective beta3-adrenoceptor agonist therapy ...

U.S. medication shortages are at a record high so far this year. Meanwhile, UnitedHealth revealed the financial impact of the ...

Zolgensma, a one-off treatment for infants born with a rare and often fatal genetic disease, came to the market five years ...

There is no advance scrutiny of listings by regulators. Generic drugmakers wishing to make a copycat version of a branded drug generally have to challenge the patents in court. But merely listing a ...

In recent years, artificial intelligence programs for drug design have steadily shown they can help explore far beyond just ...

Pivmecillinam, which has been used in Europe for decades, will become available next year to women 18 and older.

A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.

Federal prosecutors looking at relationship with Purdue Pharma and other drug manufacturers, and its role in US opioid crisis ...